Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 3/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | WNT1 | P04628 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30227653 | 0.84 | ALDH1A1 (0.48) | SSTR4SMYD3KDM4EALDH1A1HPGD | |
| SCHEMBL24151463 | 0.76 | GRM5 (0.53) | SSTR4ALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL2990215 | 0.74 | PRKAB2 (0.50) | SMYD3ALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL26944377 | 0.74 | HDAC6 (0.53) | KDM4EHPGDSAURKAAURKB | |
| SCHEMBL4251854 | 0.73 | PRKAB2 (0.49) | SSTR4SMYD3KDM4EALDH1A1CHRNB2 | |
| SCHEMBL16038662 | 0.72 | GRM5 (0.49) | SSTR4ABL1SMYD3CHRNB2CHRNB4 | |
| SCHEMBL23882445 | 0.70 | CCNT1 (0.44) | KDM4EHPGDSGSK3BDYRK1A | |
| SCHEMBL29923773 | 0.70 | KMT2A (0.47) | SSTR4KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL22725148 | 0.70 | SMYD3 (0.49) | SMYD3CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL25053100 | 0.70 | GRM5 (0.63) | SSTR4SMYD3KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203029-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF MER TYROSINE KINASE AND AXL TYROSINE KINASE | EVOTEC (UK) LIMITED (GB) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203029-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF MER TYROSINE KINASE AND AXL TYROSINE KINASE | MERTK, AXL, TYRO3 | SSTR4 1765/4885ABL1 7/4885SMYD3 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.